Home › Clovis Oncology's Phase 2 Studies of Rucaparib in Ovarian Cancer...
 

Keywords :   


Clovis Oncology's Phase 2 Studies of Rucaparib in Ovarian Cancer...

2015-05-30 21:49:00| Logistics - Topix.net

Clovis Oncology today announced updated Phase 2 results from two ongoing clinical studies with rucaparib: ARIEL2 and Study 10. Rucaparib is the Company's investigational oral, potent, small molecule inhibitor of PARP1 and PARP2 being developed for the treatment of advanced ovarian cancer, specifically in patients with BRCA mutations and other DNA repair deficiencies beyond BRCA, commonly referred to as "BRCA-like." Updated data from the ARIEL2 study in 204 patients with advanced ovarian cancer are being presented Monday in an oral presentation by Professor Iain McNeish at the 2015 American Society of Clinical Oncology annual meeting in Chicago.

Tags: studies phase cancer ovarian

Category:Transportation and Logistics

Latest from this category

All news
14.11Tropical Storm Sara Graphics
14.11Atlantic Tropical Weather Outlook
14.11Summary for Tropical Storm Sara (AT4/AL192024)
14.11Tropical Storm Sara Public Advisory Number 4A
14.11Eastern North Pacific Tropical Weather Outlook
14.11Tropical Depression Nineteen Graphics
14.11Tropical Depression Nineteen Forecast Discussion Number 4
14.11Summary for Tropical Depression Nineteen (AT4/AL192024)
Transportation and Logistics »
14.11
14.11 CD
14.11SONY4 6
14.11Max Heart
14.11c104 CD2RPGX
14.11DVD
14.11
14.11DVD
More »